CopyPastehas never been so tasty!

The Pharmaceutical Market : France

by anonymous

  • 0
  • 0
  • 0
53 views

 

France ranks alongside the UK as the second largest country in Europe in terms of population and GDP. Per capita spending on medicines continues to be one of the highest within Europe, despite measures to reduce drug consumption. The historically high levels of drug consumption stem from the fact that French patients pay relatively little for their medicines. The majority of costs are met by statutory health insurance, backed up by supplementary health insurance, which is held by over 90% of the population. Moreover, patients suffering from chronic conditions, who account for over 60% of health spending, have been exempt from drug co-payments, although new restrictions were recently introduced limiting 100% reimbursement to those drugs that are necessary to treat the chronic condition. http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/the-pharmaceutical-market-france.html

In June 2011, the Minister of Health Xavier Bertrand announced a radical reform of the French regulatory procedure. The move followed the controversy surrounding Servier’s drug Mediator, a diabetes treatment that was also used by many patients as a weight loss aid. There have been allegations that fatal side effects of the drug were hushed up by the company and also ignored by the AFSSAPS. The drug was withdrawn from the market in November 2009 due to safety concerns, and analysis has now revealed it could be responsible for up to 2,000 deaths. As part of the reform, the AFSSAPS will be changed to the National Agency for the Safety of Medicines (ANSM), and the way it is financed will be changed as it currently obtains around 80% of its funding from pharmaceutical companies. Another part of the reform is to publish a list of links between experts and laboratories, and the amount of money paid for services completed. This part of the reform has started on the 19,000 drugs in France, of which 12,000 are on the market, and Takeda’s drug Actos was the first to be removed from the market due to the new regulations. The new law also restricts visits by sales representatives and bans the pharmaceutical industry from funding medical education.

France has one of the highest pharmaceutical per capita consumption levels in the world. The French pharmaceutical market is also one of the world’s largest. The CAGR has been comparatively low and growth is expected to be comparatively low between 2012 and 2017, with government cost-containment programmes exerting downward pressure on reimbursable products. The hospital market has been much more dynamic with growth rates twice this figure in recent years, although growth rates are now falling due to greater regulatory controls in this sector and fewer innovative drugs coming to market. The underdeveloped generics market is undergoing rapid expansion, boosted by government incentives and the loss of patent protection for several high-volume products. The stagnating OTC market has also started to expand, as a result of government moves to end reimbursement for a wide range of products assigned a low medical value rating.

PROVIDING STRATEGIC MARKET ANALYSIS EVERY MONTH
Espicom's highly-regarded world pharmaceutical market research reports provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

Market size and trends impacting the development of the market.
Five-year projections for market indicators such as health spending.
Regulations on drug applications & approvals, pricing & reimbursement as well as wholesaling and retail.
Specialised intelligence on generics and biological medicines.
Foreign and local company profiles

EXECUTIVE SUMMARY.. 1
Snapshot: Strategic Espicom Analysis..2
Snapshot: Key Data Projections .....3
MACROENVIRONMENT 4
POLITICAL..4
ECONOMIC 5
LEGAL...6
EU Patent Protection & Intellectual Property Rights.....6
Proposal for Unitary Patent 6
EU Supplementary Protection Certificates...6
EU Data Exclusivity6
DEMOGRAPHIC ....7
Projections .7
Demographic Indicators...8
Birth Rate . 8
Death Rate..... 8
Infant Mortality .. 8
Life Expectancy at Birth 8
EPIDEMIOLOGY. 9
DISEASE BURDEN.9
DISEASE PREVALENCE.....9
Communicable Diseases...9
HIV/AIDS... 9
Non-communicable Diseases.....10
HEALTHCARE - ACCOMPANYING HEALTH STATISTICS .. 12
EU DIRECTIVE12
Cross-Border Healthcare Directive ..12
ORGANISATION..12
SHI..... 13
VHI..... 13
CMU-C..... 13
CNSA. 14
EXPENDITURE.....14
Projections .....14
Latest Figures.15
Pharmaceutical Expenditure . 15
INFRASTRUCTURE....16
Public Hospitals ...16
Ambulatory Care .16
SERVICES..17
Inpatient Analysis17
Ambulatory Activity..18
WORKFORCE.19
Projections .....19
Latest Figures.20
REGULATORY AFFAIRS..... 21
EU REGULATORY AUTHORITY..21
NATIONAL AUTHORITY.21
MARKETING REGISTRATION.... 22
EU Marketing Registration...22
Centralised Procedure.22
National Procedures..22
Marketing Authorisations.23
POST-MARKETING SURVEILLANCE .....24
ADVERTISING24
PRICING & REIMBURSEMENT. 25
EU NETWORKING MEETING..... 25
NM CAPR...25
PRICING... 25
Pricing Activity.....26
REIMBURSEMENT.....26
DISTRIBUTION CHANNELS..... 27
EU DIRECTIVE27
Falsified Medicines Directive27
WHOLESALING ...27
Trade Association 27
CSRP..27
Distributors....27
Alliance Healthcare27
CERP..27
OCP....28
Phoenix Pharma.....28
RETAILING..... 28
MARKET ANALYSIS 29
SIZE.... 29
Projections .....29
Historical Figures.31
Current Structure.32
PRODUCT DEVELOPMENT. 34
EU Programmes...34
Horizon 2020.....34
IMI34
Trade Association 35
ARIIS..35
R&D Expenditure.36
R&D Employees....36
Companies Specialising in R&D..37
Ipsen .37
Pierre Fabre .37
Roche37
Sanofi38
Servier....38
MANUFACTURING....39
TRADE ..... 40
Exports .....40
Imports.....43
Balance of Trade ..47
COMPETITION..48
TRADE ASSOCIATIONS . 48
LEEM ...48
LIR .48
COMPANY INTELLIGENCE.. 49
Local Manufacturers .49
Ipsen .49
Pierre Fabre .49
Sanofi50
Servier.... 51
Multinational Manufacturers.....51
AstraZeneca 51
Bristol-Myers Squibb...52
Eli Lilly.....52
GSK....52
MSD...52
Pfizer.52
Competitive Strategies ...53
GLOBAL COMPANY INTELLIGENCE ... 54
Sanofi..54
Company Overview .....54
Financial Performance 55
Product Portfolio ...56
R&D Strategy.....58
Manufacturing Capabilities....59
Outlook ..59
OTC PHARMACEUTICALS..60
MARKET SIZE 60
COMPETITION.....61
Trade Association 61
AFIPA. 61
GENERIC PHARMACEUTICALS ..... 62
REGULATION 62
EU Marketing Registration...62
PRICING & REIMBURSEMENT.. 62
Pricing.62
Generic Substitution.62
MARKET SIZE 63
COMPETITION.... 65
Trade Association 65
GEMME...65
BIOLOGICS & BIOSIMILARS....66
REGULATION 66
EU Approval Process..66
EU Regulation of Biosimilars .....66
EMA Guideline Documents...67
Draft Biosimilar Concept Paper...67
Biosimilar mAb Guideline.67
Biosimilars Approved in the EU..67
National Regulation..68
French Biomedicine Agency ..68
COMPETITION.... 68
Trade Associations.....68
Atlantic Biotherapies...68
Eurobiomed.68
France Biotech ..68
Company Intelligence.....69
AB Science....69
Carmat....69
Cellectis..69
Cerenis Therapeutics...69
Exonhit ..69
Genethon ....69
Genfit69
GenOway .....70
Hybrigenics.70
Innate Pharma ..70
Ipsogen...70
LFB.....70
Neovacs..71
NicOx 71
Sanofi Pasteur...71
Stallergenes.71
Transgene ....72
Vivalis72
Competitive Strategies ...73
CONCLUSIONS: OPPORTUNITIES & CHALLENGES ... 74
Strategic Espicom Analysis.74
MACROENVIRONMENT....74
EPIDEMIOLOGY....74
HEALTHCARE..74
REGULATORY AFFAIRS.....75
PRICING & REIMBURSEMENT75
DISTRIBUTION CHANNELS ....76
COMPETITION 77
OTC PHARMACEUTICALS.77
GENERIC PHARMACEUTICALS.....77
BIOLOGICS & BIOSIMILARS...77
Radar Analysis....79
SWOT Analysis....79
DIRECTORY 80
GOVERNMENT ORGANISATIONS.. 80
DISTRIBUTORS... 80
Leading Wholesalers.80
PRODUCERS. 80
Local Producers ...80
Multinational Producers.80
Biologic Producers.....80
TRADE ASSOCIATIONS ..81

For more information kindly visit :
The Pharmaceutical Market : France

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: https://twitter.com/BharatBook
Our Blogs: http://in.linkedin.com/pub/bharat-book/3a/98/512
http://financemarketreports.blogspot.com/

Add A Comment: